XBI News 130.36 05/02/2014 06:32:16 SPDR S&P Biotech (XBI)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
SPDR S&P Biotech (XBI) 130.36 $XBI

SPDR S&P Biotech ETF Set to Possibly Pullback After Yesterday's Rally of 1.38%
Comtex SmarTrend(R) - Thu May 01, 4:40PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $126.53 to a high of $132.49. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $129.42 on volume of 850,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Downtrend Call Working As SPDR S&P Biotech ETF Stock Falls 22.9% (XBI)
Comtex SmarTrend(R) - Mon Apr 28, 5:22PM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 2 months, SPDR S&P Biotech ETF has returned 22.86% as of today's recent price of $123.55.

Shares of XBI Down 21.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 21, 11:17AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 2 month, SPDR S&P Biotech ETF has returned 21.15% as of today's recent price of $126.28.

1 of These 3 Cratering Biotechs is a Buy
George Budwell, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
At the start of the year, the theme seemed to be that biotech was in for another banner year, propelled by a suite of newly launch drugs that would go on to become blockbusters. These rosy prognostications were made despite broad-based biotech funds...

After Yesterday's Decline of 1.71%, SPDR S&P Biotech ETF Offers Investors Better Value
Comtex SmarTrend(R) - Mon Apr 14, 4:02PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $119.06 to a high of $127.86. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $123.85 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Biotech Is Officially in a Bear Market. Is It Time to Panic?
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 3:03PM CDT
There was once a time when the biotech sector could do no wrong. Venture capital was literally coming up out of the floor to invest in the latest new development platforms. Secondary offerings were also being met with plenty of buyers. And let's not...

SPDR S&P Biotech ETF Shares Down 18.7% Since SmarTrend's Sell Call (XBI)
Comtex SmarTrend(R) - Fri Apr 11, 11:11AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 1 month, SPDR S&P Biotech ETF has returned 18.71% as of today's recent price of $130.19.

Jim Cramer's Mad Dash: HRB GILD
at The Street - Fri Apr 11, 9:38AM CDT
The tax man cometh and shows no sign of leaving, which means good news for H&R Block as it spins off its banking division, Cramer says.

Inside the Wild Ride of Biotech ETFs - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Fri Apr 11, 9:01AM CDT
Biotech ETFs have been crashing, but have all the funds been performing the same in the space?

After Yesterday's Decline of 6.40%, SPDR S&P Biotech ETF Offers Investors Better Value
Comtex SmarTrend(R) - Thu Apr 10, 5:14PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $128.38 to a high of $139.22. Yesterday, the shares fell 6.4%, which took the trading range below the 3-day low of $129.76 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

'Fast Money' Recap: The Profit-Taking Spreads
at The Street - Tue Apr 08, 4:00AM CDT
The trading panel discussed how investors are selling all sorts of sectors, including steel and home improvement.

SPDR S&P Biotech ETF Down 12.4% Since SmarTrend Downtrend Call (XBI)
Comtex SmarTrend(R) - Fri Apr 04, 9:59AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 4 weeks, SPDR S&P Biotech ETF has returned 12.45% as of today's recent price of $140.22.

SmarTrend Watching for Potential Rebound in Shares of SPDR S&P Biotech ETF After 3.56% Loss
Comtex SmarTrend(R) - Thu Apr 03, 4:37PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $137.59 to a high of $144.94. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $138.06 on volume of 932,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Any Survivors from the Biotech ETF Meltdown? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 3:00PM CDT
Although all biotech ETFs crumbled last week, many might still be well positioned for the future.

3 ETFs to Watch as Obamacare Hits Deadline - ETF News And Commentary
Sweta Killa - ZACKS - Mon Mar 31, 1:00PM CDT
Expectation for a larger base of insurers under the Obamacare put these healthcare ETFs in focus for the coming weeks.

10.3% Return Seen to Date on SmarTrend SPDR S&P Biotech ETF Call (XBI)
Comtex SmarTrend(R) - Thu Mar 27, 10:05AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 3 weeks, SPDR S&P Biotech ETF has returned 10.29% as of today's recent price of $143.67.

SPDR S&P Biotech ETF Set to Possibly Rebound After Yesterday's Selloff of 3.25%
Comtex SmarTrend(R) - Wed Mar 26, 5:02PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $141.41 to a high of $148.38. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $142.63 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fault Codes vs. Diagnosis: What's the Real Fix?

Updated Category News Views 66

When a Blink Isn’t the Whole Story Ever sat in your car, watched that check engine light flicker on, and felt your heart drop? Yeah, we've all been there. But here’s the kicker: just ‘cause that little demon’s glowing doesn’t mean your mechanic’s got all the answers. That’s where this HelloNation article steps in, trying to shed some light on the difference...

Continue Reading
National CORE Retains A+ Rating as Housing Demand Soars

Updated Category News Views 55

A Rating That Speaks Volumes in Affordable Housing Fresh out of Rancho Cucamonga, National CORE's announcement of its A+ credit rating reaffirmation is no small potatoes. For the fourth consecutive year, Standard & Poor's Global Ratings has found that this nonprofit affordable housing developer checks all the right boxes for financial strength and strategic prowess. It's...

Continue Reading
HOST's $50M Boost Fuels Avondale's Expansion

Updated Category News Views 54

Big Bucks for Avondale's Next Leap HOST isn't playing around with pocket change here. The company's coughing up a neat $50 million to propel Avondale Global Gateway into its next chapter. This investment means serious business—it’s cranking up capacity like a power plant on overdrive, laying down more rail, warehouse spaces, and dock improvements. A new...

Continue Reading
Astellas and Audax Forge $1.34B Immuno-Oncology Deal

Updated Category News Views 138

Big Moves in Immuno-Oncology: Astellas' Latest Bet You hear 'immuno-oncology,' you think breakthrough, right? Well, friends, that's what Astellas and Audax Biosciences are shooting for with their fresh handshake over DAX-044. On October 27, 2026, in Tokyo and Melbourne, the two outfits announced they're joining forces to bring this novel immunotherapy to the table. It's...

Continue Reading
Lear Capital Hits $5 Billion Milestone: Trust or Hype?

Updated Category News Views 114

A Golden Milestone or Just Glitter? Lear Capital's announcement of surpassing $5 billion in precious metals transactions feels like one of those moments where you tilt your head and ask, "Is it really what it seems?" With nearly 150,000 customers and almost three decades of hustling in the glittering world of gold and silver, they've certainly carved out a name in the...

Continue Reading
Caesarstone Loses $67.7M Case Over Artificial Stone Risks

Updated Category News Views 0

A Demand for Accountability in the Courts A Los Angeles jury recently handed down a whopping $67.7 million verdict against Caesarstone Ltd. and its U.S. operations, marking a win for Dennys Rene Rivas Williams and his family. No sugarcoating here—this is a landmark case for artificial stone fabricators suffering from silicosis. The jury found Caesarstone entities a...

Continue Reading
North Fork Mono Casino Opens: A $750 Million Bet

Updated Category News Views 62

A New Spin in Madera Cue the fanfare, folks! The North Fork Mono Casino just threw open its doors earlier than expected today, marking a hefty $750 million wager right in the heart of California's Central Valley. It's a big deal managed by Station Casinos, part of Red Rock Resorts, Inc. (NASDAQ: RRR)—teaming up with the North Fork Rancheria of Mono Indians for a...

Continue Reading
Scania's Q3 Results: A Resilient Yet Uneven Ride

Updated Category News Views 71

Scania Steadies the Ship in Q3 with Robust Growth Sailing through a patchy global market, Swedish powerhouse Scania's latest quarterly figures reflect a mixed bag of results. Their performance in this third quarter of 2026 stood strong, despite some wobbles. The company showed resilience in sales and profitability, with numbers telling a tale that's a bit like a truck...

Continue Reading
FirstEnergy Funds Boost Housing Stability Across States

Updated Category News Views 146

FirstEnergy's Commitment to Shelter and Safety You know what gives a warm feeling even in the cold, hard world of finance? Watching a company like FirstEnergy put their money where their mouth is with real action in the community. They're dishing out $125,000 in grants across West Virginia and Maryland, targeting groups that help folks dodging homelessness and domestic...

Continue Reading
DexCom Faces Scrutiny: Fiduciary Breach Questioned

Updated Category News Views 280

Is DexCom’s Leadership Under The Gun? Here's the scoop, folks—DexCom, Inc. (NASDAQ:DXCM) has been hit with some serious questions recently. Nothing like a potential fiduciary breach to shake things up. October 27, 2026, is when the news broke, with Halper Sadeh LLC taking the reins on this investigation. They’re poking around to see if DexCom’s top dogs stumbled...

Continue Reading

Top 5 Most Recently Viewed Articles

Howard Marks Analyzes AI Hype and Dot-Com Echoes in Market Trends

Updated Category News Views 192

Howard Marks Insights on Current AI Market Dynamics Respected investor Howard Marks draws significant comparisons between today’s enthusiasm for artificial intelligence (AI) and the infamous dot-com bubble of the late 1990s. He notes that identifying the long-term winners among the current wave of AI innovations is uncertain at best. Market Sentiment Transitioning from...

Continue Reading
Agnico Eagle Expands Portfolio with O3 Mining Acquisition

Updated Category News Views 161

Agnico Eagle Completes Full Acquisition of O3 Mining Agnico Eagle Mines Limited (NYSE: AEM) has successfully completed the acquisition of 100% of the outstanding common shares of O3 Mining Inc. This strategic move solidifies Agnico Eagle's position in the market and expands its asset base significantly. The acquisition was finalized through an amalgamation, integrating O3...

Continue Reading
Breakthrough Study Validates Relexxii's Comparability to Concerta

Updated Category News Views 276

New Insights on Relexxii's Efficacy Alora Pharmaceuticals, a notable player in the pharmaceutical industry, has recently announced groundbreaking findings regarding its extended-release formulation of Relexxii. This new research indicates that Relexxii is bioequivalent to the well-known reference product, Concerta, which has been a common treatment option for...

Continue Reading
Exploring the Explosive Growth of the Sports Apparel Industry

Updated Category News Views 194

The Growth of the Sports Apparel Market The global demand for sports apparel is on the rise, leading to significant growth in the industry. With cutting-edge designs and advanced technologies driving this trend, the market is projected to grow from USD 209.56 billion in 2023 to a remarkable USD 347.91 billion by 2033. This expansion is largely attributed to a growing...

Continue Reading
Peloton's Upcoming Conference Appearance: What to Know

Updated Category News Views 231

Peloton Interactive's Conference Participation Details Peloton Interactive, Inc. has officially announced an exciting opportunity for discussion and insights into their fitness solutions. Chief Financial Officer Liz Coddington will take part in a fireside chat at a prominent technology and media conference. This event is designed to engage with investors and provide...

Continue Reading